Last updated: November 2, 2026
OCTAPLAS is a pathogen-reduced, solvent/detergent-treated pooled human plasma product marketed by Octapharma. Its commercial position is based less on conventional patent exclusivity than on regulatory approval, donor-plasma access, manufacturing controls, hospital contracts, and clinical familiarity. Product-level revenue is not publicly disclosed because Octapharma is privately held and reports financial results primarily at group level. The product remains commercially relevant in plasma replacement, but its growth is constrained by competition from fresh frozen plasma, prothrombin complex concentrates, recombinant coagulation products, and blood-bank supply.
What is OCTAPLAS and how does it compete in plasma replacement?
OCTAPLAS is a standardized pooled plasma product containing multiple coagulation factors, anticoagulant proteins, and other plasma proteins. The manufacturing process includes solvent/detergent treatment designed to reduce transmission risk from enveloped viruses, followed by filtration and quality controls.
In the United States, OCTAPLAS is indicated for the replacement of multiple coagulation factors in patients with acquired deficiencies caused by conditions such as liver disease, massive transfusion, and disseminated intravascular coagulation. It is not a general substitute for every plasma-related clinical use and does not replace targeted therapies where a specific factor or reversal agent is preferred. [1]
OCTAPLAS compared with competing therapies
| Product or therapy |
Primary use |
Commercial relationship with OCTAPLAS |
| Fresh frozen plasma |
Broad replacement of coagulation factors |
Direct clinical and budget competitor |
| OCTAPLAS |
Standardized pooled, pathogen-reduced plasma |
Differentiated by manufacturing consistency and pathogen-reduction process |
| Prothrombin complex concentrate, including Kcentra |
Rapid reversal of vitamin K antagonist anticoagulation |
Important substitute in urgent bleeding and reversal protocols |
| Recombinant factor products |
Specific factor replacement |
Compete when a defined coagulation deficiency is identified |
| Cryoprecipitate and fibrinogen products |
Fibrinogen replacement |
Compete in fibrinogen-focused treatment |
| Albumin and immunoglobulins |
Different plasma-derived indications |
Use the same broad plasma-collection ecosystem but are not direct substitutes |
OCTAPLAS is most commercially defensible where hospitals value standardized composition, pathogen reduction, inventory reliability, and reduced dependence on local donor plasma processing.
What is the FDA regulatory status of OCTAPLAS?
OCTAPLAS received U.S. Food and Drug Administration approval in 2013 as a licensed biologic plasma product. The FDA approved it for acquired deficiencies of multiple coagulation factors. [1]
The U.S. product should be distinguished from regional naming conventions. Octapharma markets related solvent/detergent-treated plasma products under the OCTAPLAS and OCTAPLASLG names in different jurisdictions. The precise presentation, labeling, and regulatory pathway vary by country.
FDA regulatory attributes
| Regulatory issue |
OCTAPLAS position |
| FDA pathway |
Biologics license pathway |
| Product class |
Pooled human plasma, pathogen-reduced |
| U.S. approval |
2013 |
| Key FDA indication |
Replacement of multiple coagulation factors in acquired deficiencies |
| Orange Book status |
Not the principal U.S. reference for this biologic plasma product |
| Purple Book relevance |
More relevant than the Orange Book for biologic reference-product and biosimilar analysis |
| Prescription status |
Hospital and clinical-use product |
| Main regulatory barriers |
Donor screening, plasma collection, viral reduction, process validation, lot release, pharmacovigilance, and manufacturing inspections |
The FDA’s biologic framework makes a conventional small-molecule generic filing inappropriate. A competing manufacturer would need a biologics license and validated plasma-sourcing and manufacturing system, rather than an abbreviated new drug application based solely on chemical equivalence.
When does OCTAPLAS lose exclusivity?
OCTAPLAS does not have a clear conventional small-molecule patent cliff. Its principal commercial protections are regulatory and operational rather than a single composition-of-matter patent.
The product’s U.S. approval in 2013 could support the statutory 12-year reference-product exclusivity period applicable to many licensed biologics under the Biologics Price Competition and Innovation Act. That period would generally point to approximately 2025, subject to the product’s licensing history, statutory interpretation, and any applicable exclusivity determinations. [2]
This date does not mean that a competing product automatically enters the market in 2025. A biosimilar or interchangeable product would still require FDA approval, an adequate reference-product relationship, manufacturing capacity, plasma supply, clinical support, and commercial contracting.
Estimated exclusivity timeline
| Event |
Timing |
| U.S. approval |
2013 |
| Approximate 12-year biologic reference exclusivity endpoint |
2025 |
| Patent cliff |
No publicly established single cliff identified |
| Practical competitive opening |
Dependent on competitor licensure and manufacturing readiness |
| Current commercial protection |
Regulatory compliance, plasma supply, process know-how, contracts, and brand |
What patents protect OCTAPLAS?
The principal protection for OCTAPLAS is unlikely to reside in a dominant, long-lived composition patent. Pooled human plasma is inherently difficult to protect through conventional molecular patents because its active components are naturally occurring plasma proteins.
Potentially relevant intellectual-property categories include:
- Solvent/detergent treatment and pathogen-reduction processes.
- Plasma pooling, filtration, stabilization, and storage methods.
- Manufacturing controls and quality specifications.
- Packaging and presentation.
- Use-specific claims involving coagulation-factor replacement.
- Trademarks covering OCTAPLAS and OCTAPLASLG.
- Trade secrets involving donor selection, pool composition, process parameters, and quality release.
The commercial importance of manufacturing know-how is high. A rival would need to reproduce a consistent product while meeting requirements for viral safety, coagulation-factor activity, sterility, stability, traceability, and lot release. FDA guidance treats plasma-derived products as high-complexity biologics requiring extensive process controls. [3]
How strong is the OCTAPLAS patent estate?
The estate is stronger as a manufacturing and regulatory platform than as a classic molecule patent portfolio.
| Protection category |
Relative importance |
| Composition-of-matter patent |
Low |
| Process patent |
Moderate, depending on claim scope and expiry |
| Method-of-use patent |
Limited relative to regulatory and supply protections |
| Trademark |
High for product recognition |
| Trade secret |
High |
| Plasma collection network |
High |
| Manufacturing license and inspection history |
High |
| Hospital contracting and supply reliability |
High |
Publicly available sources do not establish a single unexpired U.S. patent that creates a product-wide OCTAPLAS entry barrier comparable to a protected small-molecule active ingredient.
Are there Paragraph IV challenges to OCTAPLAS?
A conventional Paragraph IV challenge is unlikely to be the primary pathway for OCTAPLAS because Paragraph IV litigation applies to patents listed in the FDA Orange Book for eligible drug products. OCTAPLAS is regulated as a biologic plasma product, and biologic competitors generally proceed through the Public Health Service Act framework rather than an ANDA Paragraph IV filing.
No widely reported U.S. Paragraph IV litigation involving OCTAPLAS is identified in the cited FDA and public company materials. Competitive entry would more likely involve:
- A competing licensed plasma product.
- A biosimilar or interchangeable biologic strategy, where legally applicable.
- A new biologic license supported by independent clinical and manufacturing data.
- Hospital conversion from OCTAPLAS to another pathogen-reduced plasma product.
- Procurement competition from blood centers supplying standard plasma.
The absence of a Paragraph IV case does not eliminate competitive risk. It means that the risk is more likely to arise through regulatory and procurement channels.
What formulations are protected by OCTAPLAS-related intellectual property?
OCTAPLAS is supplied as a frozen plasma product requiring controlled storage and thawing before administration. Its formulation and presentation are part of its regulatory identity, but the commercial barrier comes from process control rather than an easily copied excipient combination.
Potential formulation and presentation issues include:
- Frozen storage stability.
- Thawing conditions.
- Protein and coagulation-factor preservation.
- Container integrity.
- Lot consistency.
- Shelf-life validation.
- Compatibility with transfusion equipment.
These factors can create regulatory friction for competitors even where patent protection is limited. A rival product with a different container, thawing profile, or stability specification would need its own validation package.
What is the competitive landscape for OCTAPLAS?
The competitive landscape differs by geography.
United States
U.S. competition includes fresh frozen plasma supplied through hospital blood banks and regional blood centers, as well as other plasma-derived or coagulation-reversal products. Hospitals may use OCTAPLAS selectively because it carries a product acquisition cost that can exceed the direct cost of locally sourced plasma.
The product’s value proposition is strongest when hospitals prioritize:
- Standardized coagulation-factor content.
- Pathogen-reduction processing.
- Inventory predictability.
- Reduced dependence on local plasma processing.
- Rapid access to pooled plasma for complex coagulopathy.
Its main weakness is price sensitivity. Health systems with reliable fresh frozen plasma supply may restrict use to defined protocols.
Europe and other markets
European procurement is shaped by national blood systems, hospital purchasing, reimbursement policy, and acceptance of pathogen-reduced plasma. Octapharma has a broader commercial presence in Europe, where the company has established plasma-collection and plasma-product infrastructure.
The product competes with other pathogen-reduced plasma products, including products manufactured through alternative technologies. Local blood authorities can also influence adoption through national plasma policies and tendering.
How does OCTAPLAS compare with fresh frozen plasma?
| Attribute |
OCTAPLAS |
Fresh frozen plasma |
| Source |
Pooled human plasma |
Usually individual-donor plasma |
| Standardization |
More standardized across pools |
Greater donor-to-donor variation |
| Pathogen reduction |
Solvent/detergent treatment and related controls |
Depends on collection and regional processing |
| Supply |
Depends on Octapharma manufacturing and distribution |
Depends on local or regional blood supply |
| Cost |
Generally higher product acquisition cost |
Often lower direct acquisition cost |
| Inventory value |
Useful for predictable hospital availability |
Can be constrained by blood-group and local supply |
| Regulatory burden |
Centralized biologic manufacturing |
Blood-bank and transfusion-system controls |
| Commercial risk |
Price and contracting pressure |
Supply variability and local inventory constraints |
OCTAPLAS can gain share without displacing all fresh frozen plasma. Hospitals may use both products, with OCTAPLAS reserved for patients or settings where standardization and availability justify the premium.
What is the financial trajectory of OCTAPLAS?
OCTAPLAS product-level revenue is not separately disclosed in Octapharma’s public financial reporting. Octapharma is a privately held company, and its published results emphasize group sales across immunotherapy, hematology, critical care, and other plasma-derived products.
The company’s financial trajectory has benefited from the broader growth of plasma-derived medicines, but group performance cannot be attributed directly to OCTAPLAS. Immunoglobulins, albumin, factor products, and other therapies are significant drivers of the company’s total revenue.
Financial assessment
| Financial factor |
Effect on OCTAPLAS |
| Product-level revenue disclosure |
Limited |
| Group-level support |
Strong, through Octapharma’s manufacturing and plasma infrastructure |
| Volume growth |
Linked to hospital adoption and pathogen-reduced plasma utilization |
| Price growth |
Constrained by tenders, reimbursement, and fresh frozen plasma alternatives |
| Gross-margin support |
Manufacturing scale and centralized processing can support margins |
| Cost pressure |
Plasma collection, donor compensation, labor, energy, logistics, and quality compliance |
| Revenue visibility |
Moderate where hospitals use multiyear contracts |
| Earnings volatility |
Exposed to plasma supply and procurement cycles |
A reasonable commercial interpretation is that OCTAPLAS is a durable specialty hospital product rather than a high-growth platform equivalent to intravenous immunoglobulin. Its value is strategic because it extends Octapharma’s plasma-processing network and provides a hospital product with differentiated pathogen-reduction and standardization characteristics.
What manufacturing and supply barriers affect OCTAPLAS?
Plasma access is the central manufacturing barrier. Octapharma must secure sufficient qualified human plasma, process it under validated conditions, and maintain a global quality system. The same plasma ecosystem supports multiple products, so supply allocation can affect the company’s portfolio economics.
Major barriers include:
- Donor recruitment and retention.
- Plasma-center licensing and inspection.
- Disease screening and donor eligibility.
- Cold-chain logistics.
- Pool testing and viral safety.
- Solvent/detergent processing capacity.
- Batch release and traceability.
- Global variation in blood-product regulation.
- Hospital inventory and tender commitments.
These barriers reduce the probability of rapid commodity-style entry. They also expose OCTAPLAS to supply shocks that do not arise with chemically synthesized drugs.
What litigation and settlement activity affects OCTAPLAS?
No major publicly reported U.S. patent litigation or Paragraph IV settlement involving OCTAPLAS is identified in the cited sources. The more relevant legal risks are likely to involve:
- Product liability.
- Transfusion safety.
- Manufacturing deviations.
- Labeling and promotional compliance.
- Procurement disputes.
- Patent disputes over pathogen-reduction or plasma-processing methods.
- Contract disputes with hospitals, distributors, or blood suppliers.
The absence of a disclosed settlement does not create a legal clearance opinion. It indicates that OCTAPLAS has not generated the visible generic-litigation pattern associated with major small-molecule blockbusters.
What biosimilar risk exists for OCTAPLAS?
Biosimilar risk is moderate over the long term but limited in the near term by manufacturing complexity. A biosimilar-style entrant would need to demonstrate a high degree of similarity, control product variability, establish a qualified plasma supply chain, and obtain FDA approval under the applicable biologic pathway.
The main competitive threat may come from a different pathogen-reduced plasma product rather than a formally designated biosimilar. Blood-product manufacturers can compete through:
- Alternative pathogen-reduction technologies.
- Regional plasma networks.
- Lower hospital acquisition prices.
- Supply contracts.
- Broader transfusion-service relationships.
- Improved thawing and storage logistics.
What generic launch scenarios exist for OCTAPLAS?
| Scenario |
Probability profile |
Commercial effect |
| No direct biologic entrant, continued hospital use |
Near-term base case |
Stable but procurement-sensitive revenue |
| Competing pathogen-reduced plasma product |
More credible than an ANDA generic |
Price and contract pressure |
| Biosimilar or follow-on biologic |
Longer-term possibility |
Potential share loss if interchangeability or price advantage develops |
| Fresh frozen plasma substitution |
Persistent risk |
Limits pricing power |
| Expansion in hospitals with limited plasma processing |
Upside case |
Volume growth |
| Supply disruption or plasma shortage |
Downside case |
Lost sales, allocation, and higher costs |
How does OCTAPLAS compare with other Octapharma products?
OCTAPLAS is strategically different from Octapharma’s immunoglobulin and factor products.
| Portfolio category |
Typical commercial profile |
| Immunoglobulins |
Large demand, strong plasma dependence, often higher growth and pricing leverage |
| Hemophilia factors |
Specialist products with clinical differentiation and reimbursement sensitivity |
| Albumin |
Broad hospital use, more mature and price-sensitive |
| OCTAPLAS |
Hospital plasma replacement product with operational and supply-chain differentiation |
OCTAPLAS benefits from the company’s integrated plasma infrastructure, but it likely has lower growth and lower pricing power than high-demand immunoglobulin products.
Key Takeaways
- OCTAPLAS is a licensed pooled human plasma biologic marketed by Octapharma.
- Its U.S. approval dates to 2013, with an approximate biologic reference-exclusivity endpoint around 2025, subject to the product’s regulatory history.
- The product does not present a standard small-molecule patent cliff or conventional Paragraph IV risk.
- Its durable protections are plasma supply, validated manufacturing, regulatory compliance, trade secrets, brand recognition, and hospital contracts.
- Product-level revenue is not publicly disclosed.
- Octapharma’s group-level financial performance supports the product, but group revenue should not be treated as OCTAPLAS revenue.
- The principal commercial competitors are fresh frozen plasma, other pathogen-reduced plasma products, prothrombin complex concentrates, and targeted coagulation therapies.
- The most credible competitive threat is procurement-driven substitution or entry by another pathogen-reduced plasma manufacturer.
- Manufacturing complexity makes rapid generic entry unlikely, but it also creates exposure to donor supply, processing costs, and regulatory events.
FAQs About OCTAPLAS Market and Patent Risk
Is OCTAPLAS a biologic or a generic drug?
OCTAPLAS is a plasma-derived biologic product. It is not a conventional small-molecule drug eligible for ordinary ANDA generic substitution.
Does OCTAPLAS have an Orange Book patent listing?
OCTAPLAS is not principally managed through the Orange Book patent-listing framework used for many small-molecule drugs. Biologic reference-product and biosimilar issues are evaluated under the Public Health Service Act and the FDA’s Purple Book framework.
Can fresh frozen plasma replace OCTAPLAS?
Fresh frozen plasma can compete clinically in several plasma-replacement settings, but the products differ in standardization, pathogen-reduction processing, supply logistics, and cost.
Is OCTAPLAS approved for warfarin reversal?
OCTAPLAS is not the same as a four-factor prothrombin complex concentrate. Hospitals generally select reversal therapy based on the anticoagulant, clinical urgency, bleeding status, and applicable labeling and guidelines.
Who owns the OCTAPLAS brand?
The OCTAPLAS brand is associated with Octapharma AG and its affiliated commercial entities. The company is privately held and does not report OCTAPLAS revenue as a separate public segment.
References
- U.S. Food and Drug Administration. (2013). Octaplas prescribing information. https://www.fda.gov
- U.S. Food and Drug Administration. (2023). Implementation of the Biologics Price Competition and Innovation Act. https://www.fda.gov
- U.S. Food and Drug Administration. (2020). Compliance program guidance manual: Plasma-derived products. https://www.fda.gov
- U.S. Food and Drug Administration. (n.d.). Purple Book: Database of licensed biological products. https://purplebooksearch.fda.gov
- Octapharma AG. (n.d.). OCTAPLAS and OCTAPLASLG product information. https://www.octapharma.com
- European Medicines Agency. (n.d.). OCTAPLASLG product information. https://www.ema.europa.eu
